SETD2 and glioma: We observed a significantly higher TMB level in SETD2 mut + in colorectal cancer (P < 0.001), NSCLC (P < 0.001), melanoma (P = 0.0022), glioma (P = 0.0042), and pancreatic cancer (P = 0.00012) (Fig. 2A).